Bachurski, P. et al. 2026. Optimal First-Line Use of Pembrolizumab in Metastatic Driver-Negative NSCLC: Monotherapy Versus Chemo-Immunotherapy (Evidence 2022–2025). Quality in Sport. 51, (Jan. 2026), 68252. DOI:https://doi.org/10.12775/QS.2026.51.68252.